<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04601584</url>
  </required_header>
  <id_info>
    <org_study_id>BIM-HEM-I</org_study_id>
    <secondary_id>#652 eff date 12.11.2019</secondary_id>
    <nct_id>NCT04601584</nct_id>
  </id_info>
  <brief_title>GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL</brief_title>
  <official_title>Open-label Multicenter Non-comparative Clinical Trial of Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of GNR-084 in Patients With Refractory or Relapse Acute Lymphoblastic B-cell Precursor Leukemia in Sequential Cohorts With Dose Escalation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AO GENERIUM</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AO GENERIUM</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is an open-label dose-escalating study in sequential cohorts to assess safety and&#xD;
      pharmacokinetics of GNR-084.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute lymphoblastic leukemias (ALL) are a heterogeneous group of malignant clonal diseases of&#xD;
      the blood system originating from precursor cells of hematopoiesis, predominantly of lymphoid&#xD;
      differentiation.&#xD;
&#xD;
      More than 7,200 new cases of ALL are diagnosed annually in the European Union (EU), with&#xD;
      approximately 40% (approximately 3,000 cases) occurring in adults The main reason for the&#xD;
      failure of treatment of acute B-cell lymphoblastic leukemias (B-ALL) is the primary&#xD;
      refractoriness to chemical exposure and relapses of the disease, which actually occur in&#xD;
      40-50% of adult patients with ALL. The prognosis in these cases is regarded as extremely&#xD;
      unfavorable. Escalation of the chemotherapeutic approach is associated with the development&#xD;
      of severe toxic infectious and hemorrhagic complications.&#xD;
&#xD;
      The active substance of the preparation GNR-084 is a bispecific antibody to CD19 / CD3 in the&#xD;
      BiMS format (bispecific IgG-like molecules).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2020</start_date>
  <completion_date type="Anticipated">June 27, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 25, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Sequential dose-increase cohorts in B-ALL patients</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GNR-084 safety and tolerability.</measure>
    <time_frame>Week 10</time_frame>
    <description>The GNR-084 safety and tolerability will be assessed based on an analysis of the frequency of adverse events (AEs) over the period of treatment and observation of patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The frequency of specific toxicity events</measure>
    <time_frame>Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GNR-084 Peak Plasma Concentration (Cmax)</measure>
    <time_frame>First infusion: 5 minutes before administration, immediately after infusion, 30 minutes, 1, 3, 6, 12, 18, 24, 48, 72, 96 hours after infusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GNR-084 area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>First infusion: 5 minutes before administration, immediately after infusion, 30 minutes, 1, 3, 6, 12, 18, 24, 48, 72, 96 hours after infusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GNR-84 half-life (T1/2)</measure>
    <time_frame>First infusion: 5 minutes before administration, immediately after infusion, 30 minutes, 1, 3, 6, 12, 18, 24, 48, 72, 96 hours after infusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GNR-084 elimination rate constant (Kel)</measure>
    <time_frame>First infusion: 5 minutes before administration, immediately after infusion, 30 minutes, 1, 3, 6, 12, 18, 24, 48, 72, 96 hours after infusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GNR-084 mean retention time (MRT)</measure>
    <time_frame>First infusion: 5 minutes before administration, immediately after infusion, 30 minutes, 1, 3, 6, 12, 18, 24, 48, 72, 96 hours after infusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GNR-084 overall clearance (Cl)</measure>
    <time_frame>First infusion: 5 minutes before administration, immediately after infusion, 30 minutes, 1, 3, 6, 12, 18, 24, 48, 72, 96 hours after infusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GNR-084 kinetic volume of distribution (Vz)</measure>
    <time_frame>First infusion: 5 minutes before administration, immediately after infusion, 30 minutes, 1, 3, 6, 12, 18, 24, 48, 72, 96 hours after infusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood B-lymphocyte depletion (CD19, CD20).</measure>
    <time_frame>First infusion: 5 minutes before administration, 30 minutes, 1, 24, 48, 96 and 144 hours after infusion. Other infusions: 5 minutes before administration and 1 hour after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD45+ peripheral cell count</measure>
    <time_frame>First infusion: 5 minutes before administration, 30 minutes, 1, 24, 48, 96 and 144 hours after infusion. Other infusions: 5 minutes before administration and 1 hour after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral T-lymphocytes count (CD3, CD4, CD8)</measure>
    <time_frame>First infusion: 5 minutes before administration, 30 minutes, 1, 24, 48, 96 and 144 hours after infusion. Other infusions: 5 minutes before administration and 1 hour after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral T-memory cells (CD45RA+, CD28+, CCR7+) count</measure>
    <time_frame>First infusion: 5 minutes before administration, 30 minutes, 1, 24, 48, 96 and 144 hours after infusion. Other infusions: 5 minutes before administration and 1 hour after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral B-cells/T-cells ratio</measure>
    <time_frame>First infusion: 5 minutes before administration, 30 minutes, 1, 24, 48, 96 and 144 hours after infusion. Other infusions: 5 minutes before administration and 1 hour after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine dynamics</measure>
    <time_frame>First infusion: 5 minutes before administration, 30 minutes, 1, 24, 48, 96 and 144 hours after infusion. Other infusions: 5 minutes before administration and 1 hour after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Week 33</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>After 2 and 5 GNR-084 cycles (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete clinical and hematological remission rate (CR)</measure>
    <time_frame>After 2 and 5 GNR-084 cycles (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of complete remission with incomplete restoration of blood cellularity (CRi)</measure>
    <time_frame>After 2 and 5 GNR-084 cycles (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of an objective response (DoR)</measure>
    <time_frame>Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival (RFS)</measure>
    <time_frame>Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal residual disease (MRD) (-) rate in CR-patient</measure>
    <time_frame>After 5 GNR-084 cycles (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>B-precursor Acute Lymphoblastic Leukemia</condition>
  <condition>ALL</condition>
  <condition>GNR-084</condition>
  <arm_group>
    <arm_group_label>GNR-084, 0.01 ng/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-CD19 / CD3 antibody</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GNR-084, 0.1 ng/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-CD19 / CD3 antibody</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GNR-084, 1 ng/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-CD19 / CD3 antibody</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GNR-084, 4 ng/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-CD19 / CD3 antibody</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GNR-084, 20 ng/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-CD19 / CD3 antibody</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GNR-084, 60 ng/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-CD19 / CD3 antibody</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GNR-084, 0.01 ng/kg</intervention_name>
    <description>0.01 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles</description>
    <arm_group_label>GNR-084, 0.01 ng/kg</arm_group_label>
    <other_name>Anti-CD19 / CD3 antibody, 0.01 ng/kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GNR-084, 0.1 ng/kg</intervention_name>
    <description>0.1 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles</description>
    <arm_group_label>GNR-084, 0.1 ng/kg</arm_group_label>
    <other_name>Anti-CD19 / CD3 antibody, 0.1 ng/kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GNR-084, 1 ng/kg</intervention_name>
    <description>1 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles</description>
    <arm_group_label>GNR-084, 1 ng/kg</arm_group_label>
    <other_name>Anti-CD19 / CD3 antibody, 1 ng/kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GNR-084, 4 ng/kg</intervention_name>
    <description>4 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles</description>
    <arm_group_label>GNR-084, 4 ng/kg</arm_group_label>
    <other_name>Anti-CD19 / CD3 antibody, 4 ng/kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GNR-084, 20 ng/kg</intervention_name>
    <description>20 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles</description>
    <arm_group_label>GNR-084, 20 ng/kg</arm_group_label>
    <other_name>Anti-CD19 / CD3 antibody, 20 ng/kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GNR-084, 60 ng/kg</intervention_name>
    <description>60 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles</description>
    <arm_group_label>GNR-084, 60 ng/kg</arm_group_label>
    <other_name>Anti-CD19 / CD3 antibody, 60 ng/kg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntarily signed informed consent form to participate in the study;&#xD;
&#xD;
          2. Men and women between aged 18 to 45 inclusive;&#xD;
&#xD;
          3. Patients with incurable morphologically / immunophenotypically confirmed refractory/&#xD;
             relapse of B-cell precursors CD19-positive acute lymphoblastic leukemia from (Ph &quot;-&quot;&#xD;
             or Ph &quot;+&quot;).&#xD;
&#xD;
          4. Two or more previous lines of anti-leucosis therapy.&#xD;
&#xD;
          5. 5-50% of bone marrow blast cells at screening;&#xD;
&#xD;
          6. Functional status on the scale of the Eastern Cooperative Oncology Group (ECOG) 0-2&#xD;
             points at the screening;&#xD;
&#xD;
          7. Life expectancy ≥ 60 days;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hematopoietic stem cells transplantation within 12 weeks prior to study inclusion;&#xD;
&#xD;
          2. Active and widespread chronic graft versus host (GVHD) reaction (grade II-IV),&#xD;
             including taking immunosuppressants for the prevention and treatment of GVHD within 2&#xD;
             weeks prior the GNR-084 infusion;&#xD;
&#xD;
          3. Investigator and / or sponsor has doubts that patient will complete the study due to&#xD;
             rapid disease progression;&#xD;
&#xD;
          4. Chemotherapeutic agent using within 14 days prior the first GNR-084 infusion;&#xD;
&#xD;
             Exceptions:&#xD;
&#xD;
               -  Emergency leukapheresis;&#xD;
&#xD;
               -  Emergency hydroxyurea using due to hyperleukocytosis for ≤ 7 days;&#xD;
&#xD;
               -  Other supportive care, including antibiotics, at Investigator's discretion&#xD;
&#xD;
          5. Biochemical blood test:&#xD;
&#xD;
               -  The level of total bilirubin&gt; 1.5 upper limit of norm;&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT)&gt; 3 upper&#xD;
                  limit of norm;&#xD;
&#xD;
               -  Glomerular filtration rate (GFR) level ≤30 (СKD-EPI)&#xD;
&#xD;
          6. Medical history of blinatumomab and other bispecific antibodies using;&#xD;
&#xD;
          7. Persistent toxicity event of 3rd and 4th severity degrees (CTCAE ver 5.0) due to&#xD;
             previous treatment;&#xD;
&#xD;
          8. HIV-positive status and / or detection of any hepatitis B and / or hepatitis C blood&#xD;
             markers;&#xD;
&#xD;
          9. Severe cardiovascular diseases: uncontrolled arterial hypertension, New York Heart&#xD;
             Association (NYHA) functional class III or IV chronic heart failure, unstable angina&#xD;
             pectoris, stroke, myocardial infarction, transient ischemic attack, coronary artery&#xD;
             bypass grafting and coronary revascularization within last 12 months, or signs of&#xD;
             pericardial effusion;&#xD;
&#xD;
         10. Individual sensitivity to:&#xD;
&#xD;
               -  GNR-084 components / excipients;&#xD;
&#xD;
               -  human or humanized investigational drug antibodies;&#xD;
&#xD;
         11. Major surgical interventions, accompanied by hospitalization and anesthesia&#xD;
             application within 30 days before the patient is included in the study (biopsy is not&#xD;
             a significant surgical intervention);&#xD;
&#xD;
         12. Any other malignant neoplasm presence at the present time or within 5 years prior to&#xD;
             inclusion in the study;&#xD;
&#xD;
         13. Known suspected Central Nervous System (CNS) lesion by any genesis now or in medical&#xD;
             history, including, but not limited to: neuroleukemia, epilepsy, ischemic or&#xD;
             hemorrhagic stroke, severe traumatic brain injury, dementia, Parkinson's disease,&#xD;
             organic brain damage, cerebellar disorders, psychosis;&#xD;
&#xD;
         14. Extramedullary lesion of any localization;&#xD;
&#xD;
         15. Other clinical trials participation within 30 days before screening;&#xD;
&#xD;
         16. Mental, physical and other reasons hindering patient to adequately assess their&#xD;
             behavior and correctly comply with the conditions of the research protocol;&#xD;
&#xD;
         17. Pregnancy and / or lactation;&#xD;
&#xD;
         18. Male and female patients refusal to use adequate methods of contraception throughout&#xD;
             the study;&#xD;
&#xD;
         19. Drug addiction;&#xD;
&#xD;
         20. Alcohol addiction.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oksana A. Markova, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AO GENERIUM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eugene V. Zuev, MD</last_name>
    <phone>+7 9166419698</phone>
    <email>evzuev@generium.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Oksana A. Markova, MD</last_name>
    <phone>+7 9854418959</phone>
    <email>oamarkova@generium.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Federal State Budget Funded Institution National Medical Research Center of Hematology, Ministry of Health of the Russian Federation (MoH of Russia)</name>
      <address>
        <city>Moscow</city>
        <zip>125167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Almazov National Medical Research Centre</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191014</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pavlov First Saint Petersburg State Medical University</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>https://grls.rosminzdrav.ru/CIPermissionMini.aspx?CIStatementGUID=130bc5af-076e-46a8-b8c4-3391f5688540&amp;CIPermGUID=46966D05-6364-48D8-A949-75E71F78EADC</url>
    <description>Clinical trial registry, Ministry of Health of Russian Federation</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 13, 2020</study_first_submitted>
  <study_first_submitted_qc>October 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>GNR-084</keyword>
  <keyword>ALL</keyword>
  <keyword>Blood Diseases</keyword>
  <keyword>Precursor Cell Lymphoblastic Leukemia-Lymphoma</keyword>
  <keyword>Leukemia, Lymphoid</keyword>
  <keyword>Neoplasms by Histologic Type</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Lymphoproliferative Disorders</keyword>
  <keyword>Lymphatic Diseases</keyword>
  <keyword>Immunoproliferative Disorders</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Neoplastic Processes</keyword>
  <keyword>Pathologic Processes</keyword>
  <keyword>Antineoplastic Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

